Other News To Note

Dyax Corp., of Cambridge, Mass., said it has decided with partner Sigma-Tau Group, of Rome, to withdraw the European marketing authorization application for hereditary angioedema drug Kalbitor (ecallantide). Although Kalbitor is approved in the U.S., European regulators indicated the data were not sufficient to prove a positive risk-benefit.